NEW YORK (GenomeWeb News) – Exact Sciences today reported its revenues were flat for the second quarter year over year, while its net loss climbed sharply.

For the period ended June 30, the molecular diagnostics firm brought in revenues of $1 million, the same amount as it made during the quarter last year, matching Wall Street estimates.

All of the Madison, Wis.-based firm's revenues for the quarter were derived from license fees. It had no product royalty fees in the quarter compared to $6,000 a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: mouse genome functional analysis, more sensitive chromatin immunoprecipitation, and more.

The Center for Data Innovation and HealthITNow argue for re-building of genomic research infrastructure.

A Senate committee has unanimously approved a bill to require articles resulting from federally funded projects to be made publicly available, according to ScienceInsider.

The US is heading toward another budget showdown, Nature News says.